Skip to main content
. 2024 Sep 19;15:8220. doi: 10.1038/s41467-024-52525-w

Fig. 5. Clinical outcome of the ustekinumab treatment cohort.

Fig. 5

a Course of serum creatinine and albuminuria during ustekinumab treatment. Black arrowheads indicate cyclophosphamide and green arrowheads ustekinumab administration. Gray bands indicate low dose remission maintenance therapy with either AZA or MMF. b BVAS, ANCA levels measured via ELISA and CRP levels at baseline and 6 months after initiation ustekinumab treatment (n = 4). (CYC cyclophosphamide; AZA azathioprine; MMF mycophenolate mofetil; BVAS Birmingham Vasculitis Activity Score; CRP C-reactive protein; ACR albumin creatinine ratio). Source data are provided as a Source Data file.